# Extracellular Vesicle Associated Proteomic Biomarkers in Breast Cancer: A Systematic Review and Meta-Analysis

## TL;DR

This study reviews proteomic biomarkers in extracellular vesicles for breast cancer, identifying potential non-invasive diagnostic markers.

## Contribution

The study identifies a distinct proteomic signature in extracellular vesicles from breast cancer samples through systematic review and meta-analysis.

## Key findings

- 38 proteins were consistently differentially expressed across multiple datasets in breast cancer EVs.
- EV proteins are enriched in biological processes like cell growth, immune regulation, and tumor progression.
- Key pathways include integrin-mediated interactions, platelet activation, and hemostasis in breast cancer EVs.

## Abstract

Breast cancer continues to be the most frequently diagnosed cancer among women worldwide and remains a leading cause of cancer-related mortality. Despite advances in imaging and biopsy-based approaches, current diagnostic methods are invasive, costly, and often insufficient to capture the molecular heterogeneity of tumors. Extracellular vesicles (EVs) have emerged as promising non-invasive biomarkers owing to their role in intercellular communication and their enrichment with tumor-specific cargo. This study conducted a systematic review and meta-analysis of published literature to investigate proteomic alterations in EVs derived from breast cancer samples. From an initial 1097 records screened, four eligible studies were identified, reporting 628 differentially expressed proteins, of which 38 were consistently observed across multiple datasets. Functional enrichment analyses revealed predominant localization of these proteins to vesicle-associated compartments and significant involvement in biological processes related to cell growth, immune regulation, and tumor progression. Pathway analysis further highlighted integrin-mediated interactions, platelet activation, and hemostasis pathways as key molecular mechanisms represented within breast cancer EVs. Overall, the findings reveal a distinct EV proteomic signature in breast cancer that could support early detection and patient monitoring through minimally invasive testing. Future large-scale and standardized studies are needed to validate these candidate proteins and advance EV proteomics toward clinical application in breast cancer management.